S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biostage, Inc. stock logo
BSTG
Biostage
$4.45
$4.45
$4.45
$4.45
$61.78M-1.021,847 shsN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.60
+7.5%
$0.46
$0.37
$1.62
$2.92M0.45385,403 shs153,842 shs
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
$1.47
$8.06
$2.57
$10.42
$6.42M0.645,577 shs5 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$1.64
-3.0%
$1.87
$0.97
$5.09
$7.02M0.5929,665 shs22,280 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biostage, Inc. stock logo
BSTG
Biostage
0.00%0.00%0.00%0.00%-27.64%
Dynatronics Co. stock logo
DYNT
Dynatronics
-4.91%+39.08%+28.48%+3.11%-62.41%
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
0.00%-0.68%-2.00%+59.78%+33.64%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-3.12%-8.56%-7.57%-20.47%-60.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
1.8626 of 5 stars
3.05.00.00.02.50.00.6
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.7057 of 5 stars
3.53.00.00.00.00.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
2.00
Hold$3.80535.45% Upside
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
N/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.00
Buy$10.00509.72% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/A($0.26) per shareN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
$40.61M0.07N/AN/A$2.19 per share0.27
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
$40.21M0.16$0.63 per share2.32($14.16) per share-0.10
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$4.91M1.43N/AN/A($0.30) per share-5.47

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biostage, Inc. stock logo
BSTG
Biostage
-$6.07M-$0.58N/AN/AN/AN/A-174.43%N/A
Dynatronics Co. stock logo
DYNT
Dynatronics
-$4.97M-$1.38N/AN/A-14.13%-54.88%-16.14%5/9/2024 (Estimated)
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
$800K-$0.39N/AN/A1.99%-1.79%7.53%5/10/2024 (Estimated)
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$13.32M-$33.76N/AN/AN/A-271.04%-805.57%-97.73%N/A

Latest BSTG, IDXG, PSTV, and DYNT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/5/2024Q4 2023
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.78-$0.70+$0.08-$0.70$1.26 million$1.31 million
2/7/2024Q2 2024
Dynatronics Co. stock logo
DYNT
Dynatronics
N/A-$0.27-$0.27-$0.27N/A$8.15 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biostage, Inc. stock logo
BSTG
Biostage
N/A
2.73
2.73
Dynatronics Co. stock logo
DYNT
Dynatronics
0.21
1.41
0.67
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
N/A
0.59
0.59
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
0.92
0.92

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Biostage, Inc. stock logo
BSTG
Biostage
N/A
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
5.73%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%

Insider Ownership

CompanyInsider Ownership
Biostage, Inc. stock logo
BSTG
Biostage
15.30%
Dynatronics Co. stock logo
DYNT
Dynatronics
9.10%
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
6.50%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.32%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Biostage, Inc. stock logo
BSTG
Biostage
713.88 million11.76 millionNot Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
1544.88 million4.44 millionNot Optionable
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
1524.37 million4.08 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
204.28 million4.18 millionNot Optionable

BSTG, IDXG, PSTV, and DYNT Headlines

SourceHeadline
Plus Therapeutics, Inc. (PSTV)Plus Therapeutics, Inc. (PSTV)
finance.yahoo.com - April 19 at 12:11 AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
finance.yahoo.com - April 9 at 7:57 AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.
globenewswire.com - April 9 at 7:00 AM
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferencePlus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
finance.yahoo.com - March 27 at 10:29 AM
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell DiagnosticPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
finance.yahoo.com - March 25 at 8:51 AM
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry TailwindsBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
markets.businessinsider.com - March 23 at 7:41 AM
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal MetastasesPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
finance.yahoo.com - March 11 at 9:16 AM
Plus Therapeutics Full Year 2023 Earnings: Beats ExpectationsPlus Therapeutics Full Year 2023 Earnings: Beats Expectations
finance.yahoo.com - March 7 at 10:46 AM
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call TranscriptPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 7 at 10:46 AM
Q4 2023 Plus Therapeutics Inc Earnings CallQ4 2023 Plus Therapeutics Inc Earnings Call
finance.yahoo.com - March 6 at 6:24 PM
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
investorplace.com - March 5 at 10:33 PM
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue EstimatesPlus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
zacks.com - March 5 at 6:36 PM
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
globenewswire.com - March 5 at 4:05 PM
IMUNON stock rallies 19% on early results for COVID-19 vaccineIMUNON stock rallies 19% on early results for COVID-19 vaccine
msn.com - February 29 at 1:33 PM
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
finance.yahoo.com - February 27 at 8:49 AM
Plus Therapeutics Inc PSTVPlus Therapeutics Inc PSTV
morningstar.com - February 21 at 6:55 PM
Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0
knoxdaily.com - January 1 at 10:51 PM
Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024
finanznachrichten.de - December 18 at 1:46 PM
Plus Updates Financial and Cash Guidance for 2024Plus Updates Financial and Cash Guidance for 2024
finance.yahoo.com - December 18 at 8:46 AM
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker AnalysesPlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
finance.yahoo.com - December 12 at 10:20 AM
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)
markets.businessinsider.com - November 29 at 8:56 AM
Fortress Biotech, Plus Therapeutics among healthcare moversFortress Biotech, Plus Therapeutics among healthcare movers
msn.com - November 20 at 2:51 PM
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader WebinarPlus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
finance.yahoo.com - November 20 at 9:51 AM
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
finance.yahoo.com - November 15 at 10:12 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Biostage logo

Biostage

OTCMKTS:BSTG
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
Dynatronics logo

Dynatronics

NASDAQ:DYNT
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.
Interpace Biosciences logo

Interpace Biosciences

NASDAQ:IDXG
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Plus Therapeutics logo

Plus Therapeutics

NASDAQ:PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.